Book contents
- Imaging Biomarkers in Epilepsy
- Imaging Biomarkers in Epilepsy
- Copyright page
- Dedication
- Contents
- Preface
- Contributors
- Part I Imaging the Development and Early Phase of the Disease
- Part II Modeling Epileptogenic Lesions and Mapping Networks
- Part III Predicting the Response to Therapeutic Interventions
- Chapter 13 Prevention of Epileptogenesis in Animal Models
- Chapter 14 Imaging Mechanisms of Drug Resistance in Experimental Models of Epilepsy
- Chapter 15 Biomarkers of Drug Response and Pharmacoresistance to Epilepsy
- Chapter 16 Predicting the Outcome of Surgical Interventions for Epilepsy Using Imaging Biomarkers
- Part IV Mapping Consequences of the Disease
- Index
- References
Chapter 15 - Biomarkers of Drug Response and Pharmacoresistance to Epilepsy
from Part III - Predicting the Response to Therapeutic Interventions
Published online by Cambridge University Press: 07 January 2019
Book contents
- Imaging Biomarkers in Epilepsy
- Imaging Biomarkers in Epilepsy
- Copyright page
- Dedication
- Contents
- Preface
- Contributors
- Part I Imaging the Development and Early Phase of the Disease
- Part II Modeling Epileptogenic Lesions and Mapping Networks
- Part III Predicting the Response to Therapeutic Interventions
- Chapter 13 Prevention of Epileptogenesis in Animal Models
- Chapter 14 Imaging Mechanisms of Drug Resistance in Experimental Models of Epilepsy
- Chapter 15 Biomarkers of Drug Response and Pharmacoresistance to Epilepsy
- Chapter 16 Predicting the Outcome of Surgical Interventions for Epilepsy Using Imaging Biomarkers
- Part IV Mapping Consequences of the Disease
- Index
- References
- Type
- Chapter
- Information
- Imaging Biomarkers in Epilepsy , pp. 157 - 168Publisher: Cambridge University PressPrint publication year: 2019
References
Kwan, P, Brodie, MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–9.Google Scholar
Kwan, P, Arzimanoglou, A, Berg, A, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–77.Google Scholar
Fisher, RS, Vickrey, BG, Gibson, P, et al. The impact of epilepsy from the patient’s perspective I. Descriptions and subjective perceptions. Epilepsy Res. 2000;41:39–51.Google Scholar
Bootsma, HP, Ricker, L, Hekster, YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure. 2009;18:327–31.Google Scholar
Campos, BAG, Yasuda, CL, Castellano, G, Bilevicius, E, Li, LM, Cendes, F. Proton MRS may predict AED response in patients with TLE. Epilepsia. 2010;51:783–8.Google Scholar
Bilevicius, E, Yasuda, CL, Silva, MS, Guerreiro CAM, Lopes-Cendes I, Cendes F. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology. 2010;75:1695–701.Google Scholar
Cardoso, TAM, Coan, AC, Kobayashi, E, Guerreiro CAM, Li LM, , Cendes, F. Hippocampal abnormalities and seizure recurrence after antiepileptic drug withdrawal. Neurology. 2006;67:134–6.Google Scholar
Stretton, J, Winston, G, Sidhu, M, et al. Neural correlates of working memory in temporal lobe epilepsy—an fMRI study. NeuroImage. 2012;60:1696–703.Google Scholar
Centeno, M, Vollmar, C, O’Muircheartaigh, J, et al. Memory in frontal lobe epilepsy: an fMRI study. Epilepsia. 2012;53:1756–64.Google Scholar
de Campos, BM, Coan, AC, Lin Yasuda, C, Casseb, RF, Cendes, F. Large-scale brain networks are distinctly affected in right and left mesial temporal lobe epilepsy. Hum Brain Mapp. 2016;37(9):3137–52.Google Scholar
Vollmar, C, O’Muircheartaigh, J, Barker, GJ, et al. Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study. Brain J Neurol. 2011;134:1710–9.Google Scholar
Stretton, J, Winston, GP, Sidhu, M, et al. Disrupted segregation of working memory networks in temporal lobe epilepsy. NeuroImage Clin. 2013;2:273–81.Google Scholar
Danielson, NB, Guo, JN, Blumenfeld, H. The default mode network and altered consciousness in epilepsy. Behav Neurol. 2011;24:55–65.Google Scholar
Andrews-Hanna, JR, Reidler, JS, Sepulcre, J, Poulin, R, Buckner, RL. Functional-anatomic fractionation of the brain’s default network. Neuron. 2010;65:550–62.Google Scholar
Koepp, MJ. Gender and drug effects on neuroimaging in epilepsy. Epilepsia. 2011;52(suppl 4):35–7.Google Scholar
Mehta, MA, O’Daly, OG. Pharmacological application of fMRI. Methods Mol Biol. 2011;711:551–65.Google Scholar
Beltramini, GC, Cendes, F, Yasuda, CL. The effects of antiepileptic drugs on cognitive functional magnetic resonance imaging. Quant Imaging Med Surg. 2015;5:238–46.Google Scholar
Borsook, D, Becerra, L, Hargreaves, R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov. 2006;5:411–24.Google Scholar
Nathan, PJ, Phan, KL, Harmer, CJ, Mehta, MA, Bullmore, ET. Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. Curr Opin Pharmacol. 2014;14:54–61.Google Scholar
Jokeit, H, Okujava, M, Woermann, FG. Carbamazepine reduces memory induced activation of mesial temporal lobe structures: a pharmacological fMRI-study. BMC Neurol. 2001;1:6.Google Scholar
Haneef, Z, Levin, HS, Chiang, S. Brain graph topology changes associated with anti-epileptic drug use. Brain Connect. 2015;5:284–91.Google Scholar
Bernhardt, BC, Chen, Z, He, Y, Evans, AC, Bernasconi, N. Graph-theoretical analysis reveals disrupted small-world organization of cortical thickness correlation networks in temporal lobe epilepsy. Cereb Cortex. 2011;21:2147–57.Google Scholar
Li, X, Large, CH, Ricci, R, et al. Using interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (fMRI) and dynamic causal modeling to understand the discrete circuit specific changes of medications: lamotrigine and valproic acid changes in motor or prefrontal effective connectivity. Psychiatry Res. 2011;194:141–8.Google Scholar
Vollmar, C, O’Muircheartaigh, J, Symms, MR, et al. Altered microstructural connectivity in juvenile myoclonic epilepsy: the missing link. Neurology. 2012;78:1555–9.Google Scholar
Yacubian, EM, Wolf, P. Praxis induction. Definition, relation to epilepsy syndromes, nosological and prognostic significance. A focused review. Seizure. 2014;23:247–51.Google Scholar
Wandschneider, B, Thompson, PJ, Vollmar, C, Koepp, MJ. Frontal lobe function and structure in juvenile myoclonic epilepsy: a comprehensive review of neuropsychological and imaging data. Epilepsia. 2012;53:2091–8.Google Scholar
Szaflarski, JP, Kay, B, Gotman, J, Privitera, MD, Holland, SK. The relationship between the localization of the generalized spike and wave discharge generators and the response to valproate. Epilepsia. 2013;54:471–80.Google Scholar
Helmstaedter, C, Witt, J-A. The effects of levetiracetam on cognition: a non-interventional surveillance study. Epilepsy Behav. 2008;13:642–9.Google Scholar
Helmstaedter, C, Witt, J-A. Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial. Epilepsy Behav. 2010;18:74–80.Google Scholar
Wandschneider, B, Stretton, J, Sidhu, M, et al. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. Neurology. 2014;83:1508–12.Google Scholar
Cousijn, H, Rijpkema, M, Qin, S, van Wingen, GA, Fernández, G. Phasic deactivation of the medial temporal lobe enables working memory processing under stress. NeuroImage. 2012;59:1161–7.Google Scholar
Bakker, A, Krauss, GL, Albert, MS, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467–74.Google Scholar
Bakker, A, Albert, MS, Krauss, G, Speck, CL, Gallagher, M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. NeuroImage Clin. 2015;7:688–98.Google Scholar
Mula, M. Topiramate and cognitive impairment: evidence and clinical implications. Ther Adv Drug Saf. 2012;3:279–89.Google Scholar
Schulze-Bonhage, A. The safety and long-term efficacy of zonisamide as adjunctive therapy for focal epilepsy. Expert Rev Neurother. 2015;15:857–65.Google Scholar
Martin, R, Kuzniecky, R, Ho, S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;52:321–7.Google Scholar
Thompson, PJ, Baxendale, SA, Duncan, JS, Sander, JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69:636–41.Google Scholar
Meador, KJ, Loring, DW, Vahle, VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology. 2005;64:2108–14.Google Scholar
Bootsma, HPR, Ricker, L, Diepman, L, et al. Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure. 2008;17:19–26.Google Scholar
Mula, M, Trimble, MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009;23:121–37.Google Scholar
Ojemann, LM, Ojemann, GA, Dodrill, CB, Crawford, CA, Holmes, MD, Dudley, DL. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav. 2001;2:579–84.Google Scholar
Jansen, JFA, Aldenkamp, AP, Marian Majoie, HJ, et al. Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. Epilepsy Behav. 2006;9:181–5.Google Scholar
Szaflarski, JP, Allendorfer, JB. Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy. Epilepsy Behav. 2012;24:74–80.Google Scholar
De Ciantis, A, Muti, M, Piccolini, C, et al. A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. Neurol Sci. 2008;29(suppl 1):S141–3.Google Scholar
Yasuda, CL, Centeno, M, Vollmar, C, et al. The effect of topiramate on cognitive fMRI. Epilepsy Res. 2013;105:250–5.Google Scholar
Tang, Y, Xia, W, Yu, X, et al. Altered cerebral activity associated with topiramate and its withdrawal in patients with epilepsy with language impairment: an fMRI study using the verb generation task. Epilepsy Behav. 2016;59:98–104.Google Scholar
Raichle, ME, MacLeod, AM, Snyder, AZ, Powers, WJ, Gusnard, DA, Shulman, GL. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676–82.Google Scholar
Seghier, ML, Price, CJ. Functional heterogeneity within the default network during semantic processing and speech production. Front Psychol. 2012;3:281.Google Scholar
Wandschneider, B, Burdett, J, Townsend, L, et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology. 2017;88(12):1165–71.Google Scholar
Dodrill, CB. Effects of sulthiame upon intellectual, neuropsychological, and social functioning abilities among adult epileptics: comparison with diphenylhydantoin. Epilepsia. 1975;16:617–25.Google Scholar
Bruhn, H, Kleinschmidt, A, Boecker, H, Merboldt, KD, Hänicke, W, Frahm, J. The effect of acetazolamide on regional cerebral blood oxygenation at rest and under stimulation as assessed by MRI. J Cereb Blood Flow Metab. 1994;14:742–8.Google Scholar
van Veenendaal, TM, IJff, DM, Aldenkamp, AP, et al. Metabolic and functional MR biomarkers of antiepileptic drug effectiveness: a review. Neurosci Biobehav Rev. 2015;59:92–9.Google Scholar
Löscher, W, Klitgaard, H, Twyman, R, Schmidt, D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757–76.Google Scholar
Sisodiya, SM, Lin, WR, Harding, BN, Squier, MV, Thom, M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 2002;125:22–31.Google Scholar
Juliano, R, Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152–62.Google Scholar
Sisodiya, SM, Bates, SE. Treatment of drug resistance in epilepsy: one step at a time. Lancet Neurol. 2006;5:380–1.Google Scholar
Löscher, W, Langer, O. Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. Curr Top Med Chem. 2010;10:1785–91.Google Scholar
Bankstahl, J, Kuntner, C, Abrahim, A, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med. 2008;49:1328–35.Google Scholar
Wagner, C, Feurstein, T, Karch, R, et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)[11C]verapamil and PET. J Nucl Med. 2009;50:1192.Google Scholar
Bankstahl, J, Bankstahl, M, Kuntner, C, et al. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci. 2011;31:8803–11.Google Scholar
Bartels, AL, Kortekaas, R, Bart, J, et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. 2009;30:1818–24.Google Scholar
Brunner, M, Langer, O, Sunder-Plassmann, R, et al. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther. 2005;78:182–90.Google Scholar
Bauer, M, Karch, R, Neumann, F, et al. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab. 2010;30:510–5.Google Scholar
Eyal, S, Ke, B, Muzi, M, et al. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther. 2010;87:579–85.Google Scholar
Langer, O, Bauer, M, Hammers, A, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia. 2007;48:1774–84.Google Scholar
Feldmann, M, Asselin, M-C, Liu, J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol. 2013;12:777–85.Google Scholar
Bauer, M, Karch, R, Zeitlinger, M, et al. In vivo P-glycoprotein function before and after epilepsy surgery. Neurology. 2014;83:1326–31.Google Scholar
Jensen, S, DiPaolo, A, Lastella, M, et al. Pharmacogenetics of ABCB1 and brain kinetics of 99 m-Tc-MIBI in epilepsy patients. Epilepsia. 2006;47(suppl 3):88–9.Google Scholar
Basic, S, Hajnsek, S, Bozina, N, et al. The influence of C3435 T polymorphism of ABCB1 gene on penetration of phenobarbital across blood-brain barrier in patients with generalized epilepsy. Seizure Eur J Epilepsy. 2008;17:524–30.Google Scholar
Seneca, N, Zoghbi, SS, Liow, J-S, et al. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med. 2009;50:807–13.Google Scholar
Kreisl, W, Liow, J, Kimura, N, et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med. 2010;51:559–66.Google Scholar
Luna-Tortós, C, Fedrowitz, M, Löscher, W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008;55:1364–75.Google Scholar
Baron, J, Roeda, D, Munari, C, Crouzel, C, Chodkiewicz, J, Comar, D. Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology. 1983;33:580–5.Google Scholar
Hammers, A, Bouvard, S, Costes, N, et al. Impact of P-glycoprotein on the distribution of [18 F]-MPPF in pharmacoresistant temporal lobe epilepsia. Epilepsia. 2010;51:48.Google Scholar
Kannan, P, John, C, Zoghbi, SS, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009;86:368–77.Google Scholar
Summers, MA, Moore, JL, McAuley, JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother. 2004;38:1631–4.Google Scholar
Van Vliet, EA, Van Schaik, R, Edelbroek, PM, et al. Inhibition of the multidrug transporter p-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia. 2006;47:672–80.Google Scholar
Huls, M, Russel, FGM, Masereeuw, R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther. 2009;328:3–9.Google Scholar
Potschka, H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia. 2010;51:1333–47.Google Scholar
Potschka, H. Animal and human data: where are our concepts for drug-resistant epilepsy going? Epilepsia. 2013;54:29–32.Google Scholar